Effectiveness of Bivalent Boosters against Severe Omicron Infection.
作者信息
Lin Dan-Yu, Xu Yangjianchen, Gu Yu, Zeng Donglin, Wheeler Bradford, Young Hayley, Sunny Shadia K, Moore Zack
机构信息
University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC
North Carolina Department of Health and Human Services, Raleigh, NC.
出版信息
N Engl J Med. 2023 Feb 23;388(8):764-766. doi: 10.1056/NEJMc2215471. Epub 2023 Jan 25.
Abstract
摘要
相似文献
1
Effectiveness of Bivalent Boosters against Severe Omicron Infection.
N Engl J Med. 2023 Feb 23;388(8):764-766. doi: 10.1056/NEJMc2215471. Epub 2023 Jan 25.
2
Effects of COVID-19 vaccination and previous SARS-CoV-2 infection on omicron infection and severe outcomes in children under 12 years of age in the USA: an observational cohort study.
Lancet Infect Dis. 2023 Nov;23(11):1257-1265. doi: 10.1016/S1473-3099(23)00272-4. Epub 2023 Jun 16.
3
Vaccine Confidence and Uptake of the Omicron Bivalent Booster in Tennessee: Implications for Vulnerable Populations.
Vaccines (Basel). 2023 Apr 27;11(5):906. doi: 10.3390/vaccines11050906.
4
SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022.
MMWR Morb Mortal Wkly Rep. 2023 Jan 27;72(4):100-106. doi: 10.15585/mmwr.mm7204a4.
5
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice.
Nat Med. 2023 Jan;29(1):247-257. doi: 10.1038/s41591-022-02092-8. Epub 2022 Oct 20.
6
Neutralizing Antibody Response of the Wild-Type/Omicron BA.1 Bivalent Vaccine as the Second Booster Dose against Omicron BA.2 and BA.5.
Microbiol Spectr. 2023 Mar 22;11(2):e0513122. doi: 10.1128/spectrum.05131-22.
7
Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters.
bioRxiv. 2022 Oct 25:2022.10.24.513619. doi: 10.1101/2022.10.24.513619.
8
Bivalent Boosters against Severe Omicron Infection.
N Engl J Med. 2023 May 4;388(18):1726. doi: 10.1056/NEJMc2303753.
9
Bivalent Boosters against Severe Omicron Infection. Reply.
N Engl J Med. 2023 May 4;388(18):1726-1727. doi: 10.1056/NEJMc2303753.
10
Effectiveness of Bivalent Omicron-Containing Booster Vaccines against SARS-CoV-2 Omicron Variant among Individuals with and without Prior SARS-CoV-2 Infection.
Viruses. 2023 Aug 17;15(8):1756. doi: 10.3390/v15081756.
引用本文的文献
1
Single cell phototransfection of mRNAs encoding SARS-CoV2 spike and nucleocapsid into human astrocytes results in RNA dependent translation interference.
Front Drug Deliv. 2024 Mar 5;4:1359700. doi: 10.3389/fddev.2024.1359700. eCollection 2024.
2
Safety and Immunogenicity of aerosolized adenovirus-vectored COVID-19 vaccine and intramuscular mRNA vaccine bivalent boosters: a randomized open-label clinical trial.
Nat Commun. 2025 Aug 7;16(1):7281. doi: 10.1038/s41467-025-62698-7.
3
Nanotechnology-based mRNA vaccines.
Nat Rev Methods Primers. 2023;3(1). doi: 10.1038/s43586-023-00246-7. Epub 2023 Aug 17.
4
Universal Bacterium-Vectored COVID-19 Vaccine Expressing Early SARS-CoV-2 Conserved Proteins Cross-Protects Against Late Variants in Hamsters.
Vaccines (Basel). 2025 Jun 12;13(6):633. doi: 10.3390/vaccines13060633.
5
Estimating population immunity to SARS-CoV-2 by random sampling from primary and secondary healthcare in Scotland, May 2024.
EBioMedicine. 2025 Jun;116:105760. doi: 10.1016/j.ebiom.2025.105760. Epub 2025 May 16.
6
Effectiveness of a single COVID-19 mRNA vaccine dose in individuals with prior SARS-CoV-2 infection: a systematic review.
Commun Med (Lond). 2025 May 3;5(1):151. doi: 10.1038/s43856-025-00882-y.
7
Optimal Timing of Vaccination: A Narrative Review of Integrating Strategies for COVID-19, Influenza, and Respiratory Syncytial Virus.
Infect Dis Ther. 2025 May;14(5):911-932. doi: 10.1007/s40121-025-01135-0. Epub 2025 Apr 10.
8
mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine in healthy adults: a phase 1/2 trial.
Nat Med. 2025 May;31(5):1484-1493. doi: 10.1038/s41591-025-03591-0. Epub 2025 Mar 18.
9
Exploring Temporal and Spatial Characteristics of Serious Adverse Event Reports Following COVID-19 Bivalent Vaccines.
Res Sq. 2025 Mar 3:rs.3.rs-6096098. doi: 10.21203/rs.3.rs-6096098/v1.
10
Limitations of neutralizing antibody titers in COVID-19 vaccine efficacy trials and a call for additional correlates of protection.
Hum Vaccin Immunother. 2025 Dec;21(1):2473795. doi: 10.1080/21645515.2025.2473795. Epub 2025 Mar 7.
本文引用的文献
1
Association of Primary and Booster Vaccination and Prior Infection With SARS-CoV-2 Infection and Severe COVID-19 Outcomes.
JAMA. 2022 Oct 11;328(14):1415-1426. doi: 10.1001/jama.2022.17876.
2
Effects of Vaccination and Previous Infection on Omicron Infections in Children.
N Engl J Med. 2022 Sep 22;387(12):1141-1143. doi: 10.1056/NEJMc2209371. Epub 2022 Sep 7.
3
Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina.
N Engl J Med. 2022 Mar 10;386(10):933-941. doi: 10.1056/NEJMoa2117128. Epub 2022 Jan 12.
Zotero 插件